GLAXO Q4 FY26 Guidance vs Delivery (GLAXO Management Mirror)

Revenue Growth

Management maintains its ambition for double-digit top-line growth. In the Mar'26 Qtr, General Medicines is expected to normalize at 6% to 8% growth, while vaccines are guided for strong high double-digit growth in the coming year. Previously, the Dec'25 Qtr initiated a five-to-seven-year target to double total business revenues to INR 8,000 crores, requiring a 12% to 13% annual growth rate. [Status: Reaffirmed]